Applied Biosystems Selects Medical Solutions Geneservice to be UK Service Provider for SNPlex™ Genotyping System
News Aug 21, 2007
The Board of Medical Solutions plc has announced that its recently acquired genomic services and products business Geneservice Limited has been chosen by Applied Biosystems to be the UK service provider of its SNPlex™ Genotyping System and help broaden access to its genotyping technology.
• Geneservice to benefit from marketing and technical support.
• Geneservice was selected because of its proven proficiency in executing the SNPlex™ chemistry workflow.
• SNPlex™ platform will enhance Geneservices’ delivery of advanced genotyping services.
As part of Applied Biosystems’ SNPlex™ Service Provider Program, Geneservice will benefit from marketing and technical support - which is expected to enhance its ability to deliver advanced genotyping services to its clients.
Geneservice will use the Applied Biosystems’ SNPlex™ technology and genotyping and sequencing platforms to offer a system for projects needing to genotype multiple single nucleotide polymorphisms (SNPs) from hundreds or thousands of samples.
The SNPlex™ Service Provider Program is intended to enable researchers who do not have access to capillary electrophoresis (CE) genetic analysis instrumentation to obtain a flexible and bespoke high-throughput SNP genotyping data solution.
Nick Leaves, Head of Operations for Medical Solutions said: "The SNPlex™ Genotyping System is well suited to the candidate gene association studies that typically follow whole-genome screening. We already have significant expressions of interest in SNPlex™ and have completed over 900,000 custom SNP genotypes in recent months. We are delighted to have had our experience recognised by Applied Biosystems and to have been chosen as its partner for this technology in the UK.”
CRISPR Causes More Genome Damage Than First ThoughtNews
Researchers have discovered that CRISPR/Cas9 gene editing can cause greater genetic damage in cells than was previously thought. These results create safety implications for gene therapies using CRISPR/Cas9 in the future as the unexpected damage could lead to dangerous changes in some cells.
Potential Treatment for Rare Inherited CancersNews
Studying two rare inherited cancer syndromes, scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery suggests a promising strategy for treatment with drugs recently approved for other forms of cancer, said the researchers.READ MORE